Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Catalyst Biosciences stock
Learn how to easily invest in Catalyst Biosciences stock.
Catalyst Biosciences is a biotechnology business based in the US. Catalyst Biosciences shares (CBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Biosciences employs 45 staff and has a trailing 12-month revenue of around $3.2 million.
How to buy Catalyst Biosciences stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – CBIO. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
Catalyst Biosciences stock price (NASDAQ: CBIO)Use our graph to track the performance of CBIO stocks over time.
Catalyst Biosciences shares at a glance
|Latest market close||$0.30|
|52-week range||$0.20 - $1.29|
|50-day moving average||$0.51|
|200-day moving average||$0.43|
|Wall St. target price||$16.00|
|Dividend yield||$1.43 (0%)|
|Earnings per share (TTM)||$0.42|
Buy Catalyst Biosciences stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Catalyst Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Catalyst Biosciences price performance over time
|1 week (2023-01-23)||11.11%|
|1 month (2022-12-30)||-43.40%|
|3 months (2022-10-28)||-48.35%|
|6 months (2022-07-29)||-82.86%|
|1 year (2022-01-26)||N/A|
|2 years (2021-01-29)||-94.69%|
|3 years (2020-01-30)||7.51|
|5 years (2018-01-30)||42.54|
Is Catalyst Biosciences stock undervalued or overvalued?
Valuing Catalyst Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Biosciences's P/E ratio
Catalyst Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Catalyst Biosciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Biosciences's PEG ratio
Catalyst Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Catalyst Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Catalyst Biosciences financials
|Revenue TTM||$3.2 million|
|Gross profit TTM||$-64,906,000|
|Return on assets TTM||-46.47%|
|Return on equity TTM||26.37%|
|Market capitalisation||$11.4 million|
TTM: trailing 12 months
Catalyst Biosciences share dividends
Dividend payout ratio: 4.39% of net profits
Recently Catalyst Biosciences has paid out, on average, around 4.39% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Catalyst Biosciences shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Catalyst Biosciences's case, that would currently equate to about $1.43 per share.
While Catalyst Biosciences's payout ratio might seem low, this can signify that Catalyst Biosciences is investing more in its future growth.
Catalyst Biosciences's most recent dividend payout was on 11 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 12 January 2023 (the "ex-dividend date").
Have Catalyst Biosciences's shares ever split?
Catalyst Biosciences's shares were split on a 1:15 basis on 12 February 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catalyst Biosciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Catalyst Biosciences shares which in turn could have impacted Catalyst Biosciences's share price.
Catalyst Biosciences share price volatility
Over the last 12 months, Catalyst Biosciences's shares have ranged in value from as little as $0.2 up to $1.2939. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Biosciences's is 1.3757. This would suggest that Catalyst Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Biosciences overview
Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc. ; and license and collaboration agreement with Biogen International GmbH.
Catalyst Biosciences in the news
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, CBIO
SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – HZN, CBIO, SAFE, IAA
Frequently asked questionsWhat percentage of Catalyst Biosciences is owned by insiders or institutions?
Currently 26.07% of Catalyst Biosciences shares are held by insiders and 20.896% by institutions. How many people work for Catalyst Biosciences?
Latest data suggests 45 work at Catalyst Biosciences. When does the fiscal year end for Catalyst Biosciences?
Catalyst Biosciences's fiscal year ends in December. Where is Catalyst Biosciences based?
Catalyst Biosciences's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080 What is Catalyst Biosciences's ISIN number?
Catalyst Biosciences's international securities identification number is: US14888D2080 What is Catalyst Biosciences's CUSIP number?
Catalyst Biosciences's Committee on Uniform Securities Identification Procedures number is: 14888D109
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert